Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
cinitapride
- Development stage
- Phase 3
- Lead developer
- Almirall
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Cinitapride is a gastroprokinetic and antiemetic agent of the benzamide class. It is primarily used to treat gastrointestinal motility disorders such as gastroesophageal reflux disease (GERD), non-ulcer dyspepsia, delayed gastric emptying (gastroparesis), and functional dyspepsia. Cinitapride acts as an agonist at serotonin 5-HT1 and 5-HT4 receptors and as an antagonist at the serotonin 5-HT2 receptor. Additionally, it has some antagonistic activity at dopamine D2 receptors. Its mechanism enhances gastrointestinal motility by increasing acetylcholine release in the enteric nervous system, thereby improving gastric emptying and reducing symptoms like nausea and vomiting. The drug was developed by Almirall and is marketed in countries including Spain, Mexico, India, Pakistan, and others[1][3][4][7].
- Brand names
- CintaproPemixCT PRIDE 1
- Other names
- CinitapridaCidine
02
Targets
HTR2A (Serotonin receptor 5-HT2A)HTR4 (5-Hydroxytryptamine receptor 4)DRD2 (Dopamine D2 Receptor)HTR1A (Serotonin receptor 1A (5-hydroxytryptamine receptor 1A))
Beyond the preview
Go deeper on cinitapride.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on cinitapride.